MX2018011721A - Compuesto de griseofulvina. - Google Patents
Compuesto de griseofulvina.Info
- Publication number
- MX2018011721A MX2018011721A MX2018011721A MX2018011721A MX2018011721A MX 2018011721 A MX2018011721 A MX 2018011721A MX 2018011721 A MX2018011721 A MX 2018011721A MX 2018011721 A MX2018011721 A MX 2018011721A MX 2018011721 A MX2018011721 A MX 2018011721A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl group
- compound
- acceptable salt
- pharmacologically acceptable
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Un objeto de la presente invención es proporcionar un compuesto que tiene una actividad antiinflamatoria o una sal farmacológicamente aceptable del mismo. La solución de la presente invención es un compuesto de la fórmula general (1) o una sal farmacológicamente aceptable del mismo. (ver Fórmula) en donde los símbolos en la fórmula se definen a continuación: R1: por ejemplo, un grupo C1-C6alquilo; R2: un grupo C1-C6alquilo; A: por ejemplo, un átomo de oxígeno; y R3: por ejemplo, un grupo C1-C6alquilo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016067076 | 2016-03-30 | ||
| PCT/JP2017/012777 WO2017170623A1 (ja) | 2016-03-30 | 2017-03-29 | グリセオフルビン化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018011721A true MX2018011721A (es) | 2019-01-10 |
Family
ID=59965779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011721A MX2018011721A (es) | 2016-03-30 | 2017-03-29 | Compuesto de griseofulvina. |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US10570109B2 (es) |
| EP (2) | EP4032883A1 (es) |
| JP (1) | JP6808715B2 (es) |
| KR (1) | KR102419232B1 (es) |
| CN (1) | CN108779089B (es) |
| AU (1) | AU2017244777B2 (es) |
| BR (1) | BR112018069712B1 (es) |
| CA (1) | CA3018316C (es) |
| CO (1) | CO2018010787A2 (es) |
| DK (1) | DK3438103T3 (es) |
| ES (1) | ES2908221T3 (es) |
| HU (1) | HUE058182T2 (es) |
| IL (1) | IL262020B (es) |
| MX (1) | MX2018011721A (es) |
| MY (1) | MY195881A (es) |
| PH (1) | PH12018502012A1 (es) |
| PL (1) | PL3438103T3 (es) |
| PT (1) | PT3438103T (es) |
| RU (1) | RU2736208C2 (es) |
| SG (1) | SG11201808171PA (es) |
| TW (1) | TWI738751B (es) |
| WO (1) | WO2017170623A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6808715B2 (ja) | 2016-03-30 | 2021-01-06 | 第一三共株式会社 | グリセオフルビン化合物 |
| TWI811243B (zh) * | 2017-09-29 | 2023-08-11 | 日商第一三共股份有限公司 | 灰黃黴素化合物及醫藥用途 |
| CN108329291B (zh) * | 2018-01-31 | 2021-07-09 | 青岛理工大学 | 一种离子液体催化的9-蒽酮内酯类化合物的合成方法 |
| US20230136792A1 (en) * | 2020-04-02 | 2023-05-04 | Sirtsei Pharmaceuticals, Inc. | Compositions and methods for treating age-related diseases and premature aging disorders |
| CN113861144B (zh) * | 2021-08-04 | 2022-06-21 | 南通大学 | 一种灰黄霉素开环衍生物及其制备方法 |
| CN117229246A (zh) * | 2023-05-23 | 2023-12-15 | 湖北天勤生物科技有限公司 | 具有抗炎活性的化合物及其制备方法和用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03255081A (ja) * | 1990-03-01 | 1991-11-13 | Mect Corp | ｄｌ―グリセオフルビン、ｄｌ―グリセオフルビン誘導体およびそれらの中間体の製造方法 |
| DE4430910A1 (de) | 1994-08-31 | 1996-03-07 | Eisele Rolf Dipl Ing Fh | Arzneimittel gegen Tinnitus |
| US20060100181A1 (en) | 2002-05-03 | 2006-05-11 | Jost-Price Edward R | Combinations for the treatment of inflammatory skin disorders |
| EP2008652A1 (en) * | 2007-06-28 | 2008-12-31 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering |
| EP2204367A1 (en) | 2008-12-22 | 2010-07-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering |
| WO2010124695A1 (fr) | 2009-04-26 | 2010-11-04 | Soumia Goutali | Utilisation de la griseofulvine dans l'amelioration des facultes mentales: attention, concentration et memoire |
| EP2880024A1 (fr) * | 2012-08-01 | 2015-06-10 | Pierre Fabre Medicament | Derives de griseofulvine |
| CN104860909B (zh) * | 2015-04-09 | 2017-03-08 | 西北农林科技大学 | 灰黄霉素衍生物、灰黄霉素及其衍生物的抗菌活性应用 |
| JP6808715B2 (ja) | 2016-03-30 | 2021-01-06 | 第一三共株式会社 | グリセオフルビン化合物 |
| TWI811243B (zh) | 2017-09-29 | 2023-08-11 | 日商第一三共股份有限公司 | 灰黃黴素化合物及醫藥用途 |
-
2017
- 2017-03-29 JP JP2018508114A patent/JP6808715B2/ja active Active
- 2017-03-29 HU HUE17775160A patent/HUE058182T2/hu unknown
- 2017-03-29 PL PL17775160T patent/PL3438103T3/pl unknown
- 2017-03-29 RU RU2018137851A patent/RU2736208C2/ru active
- 2017-03-29 MY MYPI2018001614A patent/MY195881A/en unknown
- 2017-03-29 US US16/088,696 patent/US10570109B2/en active Active
- 2017-03-29 KR KR1020187027758A patent/KR102419232B1/ko active IP Right Grant
- 2017-03-29 ES ES17775160T patent/ES2908221T3/es active Active
- 2017-03-29 MX MX2018011721A patent/MX2018011721A/es unknown
- 2017-03-29 PT PT177751609T patent/PT3438103T/pt unknown
- 2017-03-29 DK DK17775160.9T patent/DK3438103T3/da active
- 2017-03-29 WO PCT/JP2017/012777 patent/WO2017170623A1/ja active Application Filing
- 2017-03-29 AU AU2017244777A patent/AU2017244777B2/en active Active
- 2017-03-29 EP EP21212977.9A patent/EP4032883A1/en active Pending
- 2017-03-29 CA CA3018316A patent/CA3018316C/en active Active
- 2017-03-29 BR BR112018069712-5A patent/BR112018069712B1/pt active IP Right Grant
- 2017-03-29 EP EP17775160.9A patent/EP3438103B1/en active Active
- 2017-03-29 CN CN201780017933.3A patent/CN108779089B/zh active Active
- 2017-03-29 TW TW106110433A patent/TWI738751B/zh active
- 2017-03-29 SG SG11201808171PA patent/SG11201808171PA/en unknown
-
2018
- 2018-09-19 PH PH12018502012A patent/PH12018502012A1/en unknown
- 2018-09-27 IL IL262020A patent/IL262020B/en unknown
- 2018-10-08 CO CONC2018/0010787A patent/CO2018010787A2/es unknown
-
2019
- 2019-09-05 US US16/561,459 patent/US10654821B2/en active Active
-
2020
- 2020-04-09 US US16/844,621 patent/US10975052B2/en active Active
-
2021
- 2021-03-25 US US17/212,373 patent/US11472784B2/en active Active
-
2022
- 2022-10-13 US US18/046,270 patent/US11834427B2/en active Active
-
2023
- 2023-11-03 US US18/501,481 patent/US20240150309A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502012A1 (en) | Griseofulvin compound | |
| MY152972A (en) | Azabicyclo compound and salt thereof | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MX2013006101A (es) | Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos. | |
| PH12019500811A1 (en) | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors | |
| EP4316591A3 (en) | Oxysterols and methods of use thereof | |
| TN2011000400A1 (en) | Inhibitors of beta-secretase | |
| MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
| BR112016007427A2 (pt) | compostos de pirazol-amida e usos dos mesmos | |
| MX2020009234A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos. | |
| EP4248968A3 (en) | Tlr7/8 antagonists and uses thereof | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| AU2018253590A1 (en) | Imidazopyridazine compounds | |
| MX348084B (es) | Compuestos de cetolido. | |
| MX2020000576A (es) | Compuestos quimicos. | |
| MX2013000295A (es) | Procedimiento de preparacion de un inhibidor especifico de la trombina. | |
| MX2016005993A (es) | Anfifilos biscationicos y triscationicos como agentes antimicrobianos. | |
| MY169179A (en) | Novel piperidine compound or salt thereof | |
| PH12020550168A1 (en) | Griseofulvin compound and pharmaceutical use thereof | |
| UY37764A (es) | Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds) | |
| MD20160105A2 (ro) | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide | |
| MY170262A (en) | Dicarboxylic acid compound | |
| UA103329C2 (ru) | Соли соединений-ингибиторов вич | |
| TN2021000025A1 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
| BR112013015604A2 (pt) | novo derivado de isoquinolina substituído |